Teva, Momenta Slide After Mylan Gets Earlier Than Expected MS Drug Nod
October 04, 2017 at 15:52 PM EDT
Shares of Mylan are soaring after the company announced that the Food and Drug Administration had approved its generic version of Teva Pharmaceutical's multiple sclerosis treatment Copaxone.
